Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abvc Biopharma (ABVC) Shares Outstanding (Diluted Average) (2021 - 2024)

Abvc Biopharma (ABVC) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $20.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) changed N/A year-over-year to $20.1 million, compared with a TTM value of $20.1 million through Dec 2025, changed N/A, and an annual FY2025 reading of $20.1 million, changed N/A over the prior year.
  • Shares Outstanding (Diluted Average) was $20.1 million for Q4 2025 at Abvc Biopharma, up from $18.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $33.1 million in Q1 2023 and bottomed at $3.0 million in Q2 2022.
  • Average Shares Outstanding (Diluted Average) over 5 years is $14.4 million, with a median of $11.9 million recorded in 2024.
  • The sharpest move saw Shares Outstanding (Diluted Average) crashed 87.85% in 2022, then skyrocketed 242.26% in 2024.
  • Year by year, Shares Outstanding (Diluted Average) stood at $25.1 million in 2021, then plummeted by 87.36% to $3.2 million in 2022, then skyrocketed by 36.92% to $4.3 million in 2023, then skyrocketed by 186.12% to $12.4 million in 2024, then soared by 62.1% to $20.1 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for ABVC at $20.1 million in Q4 2025, $18.6 million in Q3 2025, and $12.4 million in Q3 2024.